GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2008

Oncolytics Transfers 40 L cGMP Manufacturing Process for Anticancer Agent to SAFC Pharma

  • Oncolytics Biotech reports successfully transferred cGMP production for its cancer drug candidate at the 40-liter batch size to SAFC Pharma. The compound Reolysin is in multiple clinical programs in different cancer types.

    Yields at the 40-litre scale should provide sufficient doses to support future development plans leading to registration and the anticipated early-stage commercial requirements, notes Oncolytics. Development work to support further scale-up to the 100-litre level is currently under way.

    “Consistent with our previous announcement of a $12 million expansion of capacity, we will be in a position to support commercial production of Reolysin,” says Jeffrey L. Strobel, Ph.D., site director at SAFC Pharma’s operation in Carlsbad, CA. The Carlsbad facility supports the viral vector and vaccine community with its process development and analytical laboratory expertise as well as its cGMP capability, he adds.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »